Minimally invasive surgery cuts costs in liver and pancreatic procedures
Minimally invasive approaches in liver and pancreatic surgery show significant cost advantages.
Newsletter
Every new paper in this field, in your inbox.
Minimally invasive approaches in liver and pancreatic surgery show significant cost advantages.
Upfront endoscopic necrosectomy (UEN) and step-up endoscopic necrosectomy (SUEN) show similar outcomes for walled-off pancreatic necrosis, impacting how you approach patient management.
This study examines the effectiveness of different biliary stents for treating bile leaks post-fenestrated cholecystectomy, revealing significant implications for patient management.
Neoadjuvant GOLP therapy significantly enhances event-free survival in patients with resectable high-risk intrahepatic cholangiocarcinoma.
Medicaid expansion improves survival and surgical access for pancreatic cancer patients.
Transplanting liver patients who respond to atezolizumab-bevacizumab is promising for those with intermediate and advanced hepatocellular carcinoma.
Dynamic radiomic features from MRI can predict complete response in hepatocellular carcinoma (HCC) post-immune therapy, critical for surgical planning.
Atezolizumab-bevacizumab shows promising long-term survival for patients with unresectable hepatocellular carcinoma.
Salvaging the spleen shows lower mortality and complications than splenectomy in severe blunt splenic injuries for trauma patients.
Piperacillin-tazobactam reduces surgical site infections compared to cefoxitin, impacting long-term surgical outcomes for pancreatoduodenectomy patients.